The effects of S-allylmercaptocaptopril, the synthetic product of allicin and captopril, on cardiovascular risk factors associated with the metabolic syndrome.
Pure allicin, prepared biosynthetically by reacting synthetic alliin with an immobilized alliinase enzyme, is known to possess cardioprotective effects. However, in its pure form, allicin is pharmacologically unstable. S-allylmercaptocaptopril (CPSSA) is a new stable synthetic compound produced by chemical reaction between allicin and the angiotensin converting enzyme inhibitor captopril. Using the fructose-induced metabolic syndrome rat model we studied the effects of short-term treatment with two doses of CPSSA on cardiovascular risk factors associated with the metabolic syndrome, in comparison to the effects of allicin and captopril separately. Allicin (8 mg/(kg day)) significantly reduced insulin, triglycerides, and homocysteine concentrations, and had a slight effect on SBP. Captopril (50mg/(kg day)) only improved blood pressure and homocysteine. Treatment with low dose of CPSSA (5mg/(kg day)) lowered SBP but did not improve any other measured parameter, while treatment with a higher dose (50mg/(kg day)) significantly decreased blood pressure, triglycerides, and homocysteine concentrations. We conclude that the combined molecule CPSSA integrates the anti-hypertensive, lipid-lowering, and homocysteine-reducing effects of both allicin and captopril, making it a potential cardiovascular protective agent.
Oron-Herman
Mor
M
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. mor.oron@sheba.health.gov.il
Rosenthal
Talma
T
Mirelman
David
D
Miron
Talia
T
Rabinkov
Aharon
A
Wilchek
Meir
M
Sela
Ben-Ami
BA
D000818:Animals; D000959:Antihypertensive Agents / Q000737:chemistry / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000737:chemistry / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000138:chemical synthesis / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004220:Disulfides; D006710:Homocysteine / Q000097:blood / Q000187:drug effects; D006973:Hypertension / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012307:Risk Factors; D013441:Sulfinic Acids / Q000737:chemistry / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D000959:Antihypertensive Agents; D003521:Cyclopropanes; D004220:Disulfides; D007004:Hypoglycemic Agents; D007328:Insulin; D013441:Sulfinic Acids; D014280:Triglycerides; D006710:Homocysteine; C048914:1-formylcyclopropane-2-carboxylic acid; C006452:allicin; D002216:Captopril